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Mitral regurgitation in patients with severe 
aortic stenosis: diagnosis and management
Anna Sannino, Paul A Grayburn
AbstrAct
Severe aortic stenosis (AS) and mitral regurgitation (MR) 
frequently coexist. Although some observational studies 
have reported that moderate or severe MR is associated 
with higher mortality, the optimal management of such 
patients is still unclear. Simultaneous replacement of 
both aortic and mitral valves is linked to significantly 
higher morbidity and mortality. Recent advances in 
minimally invasive surgical or transcatheter therapies 
for MR allow for staged procedures in which surgical 
or transcatheter aortic valve replacement (SAVR/TAVR) 
is done first and MR severity re-evaluated afterwards. 
Current evidence suggests MR severity improves in 
some patients after SAVR or TAVR, depending on 
several factors (MR aetiology, type of valve used for 
TAVR, presence/absence of atrial fibrillation, residual 
aortic regurgitation, etc). However, as of today, the 
absence of randomised clinical trials does not allow for 
evidence-based recommendations about whether or not 
MR should be addressed at the time of SAVR or TAVR. 
A careful patient evaluation and clinical judgement are 
recommended to distinguish patients who might benefit 
from a double valve intervention from those in which 
MR should be left alone. The aim of this review is to 
report and critique the available data on this subject in 
order to help guide the clinical decision making in this 
challenging subset of patients.
IntroductIon
Mitral regurgitation (MR) is commonly observed in 
patients with severe aortic stenosis (AS).1 However, 
conflicting data exist regarding the impact of MR 
on outcomes after surgical or transcatheter aortic 
valve replacement (SAVR or TAVR). It is known that 
simultaneous surgical replacement of both aortic and 
mitral valves significantly increases morbidity and 
mortality, especially in elderly patients (in-hospital 
mortality rates 5%–12.5%).2 3 The success of TAVR as 
a therapy for severe AS, along with the development 
of transcatheter therapies for MR, offers the option 
of a staged procedure to address AS first, and then 
reassess MR severity afterwards. This is particularly 
relevant since moderate or severe MR may improve 
in some patients following SAVR or TAVR. Because 
of the paucity of high-quality data on this topic, the 
2014 American Heart Association/American College 
of Cardiology guidelines opted not to make recom-
mendations regarding double valve procedures in 
patients with AS and MR.4 This review focuses on the 
available evidence regarding 1) the impact of MR on 
outcomes of patients with severe AS, 2) spontaneous 
improvement in MR severity after SAVR or TAVR 
and 3) when it is reasonable to intervene on mitral 
valve at the time of SAVR or TAVR, versus a staged 
procedure or leaving MR untreated.
Assessment of Mr in patients with  
concomitant As
The valve guidelines emphasise the importance of 
distinguishing whether MR is primary (ie, caused by 
leaflet abnormality) or secondary to left ventricular 
(LV) dilation and dysfunction.4 The most common 
cause of primary MR in the general population of 
high-income countries is mitral valve prolapse,5 
whereas the most common cause of secondary MR 
is ischaemic cardiomyopathy.6 In secondary MR, the 
leaflets are normal (or have only minor age-related 
thickening), with restricted systolic closure caused 
by tethering because of outward displacement of 
the LV walls and papillary muscles, with or without 
annular dilation.6 7 However, in patients with severe 
AS, the mitral annulus, leaflets and subvalvular 
apparatus often are calcified to varying degrees 
and the LV size and function are typically normal. 
Thus, the classical definition of secondary MR is 
seldom met. Patients with AS and LV dysfunction, 
either due to ischaemic heart disease or the effects 
of chronic pressure overload, may have leaflet teth-
ering, but usually also have some degree of leaflet 
or annular calcification, and thus mixed aetiology 
MR. The presence of normal mitral valve leaflets in 
a patient with severe AS may be a clue to the pres-
ence of a bicuspid valve. Occasionally, patients with 
AS are observed to have mitral valve prolapse or a 
flail leaflet, often with mitral annular calcification. 
Figure 1 shows examples of mitral valve patholo-
gies in patients with severe AS. Transthoracic or 
transoesophageal echocardiography is the reference 
standard for determining the mechanism of MR 
and the feasibility of mitral valve repair.8 However, 
the echocardiographic evaluation of the severity of 
MR is complex with no single parameter having 
sufficient accuracy and reproducibility to serve as 
the sole arbiter of MR severity. Thus, integration 
of multiple echocardiographic findings, including 
quantitative measurements, is recommended in 
clinical practice.8–11 This can be more challenging 
in AS due to attenuation of ultrasound by calcifi-
cation. Colour Doppler jet size tends to overesti-
mate MR severity in classic AS due to the increased 
LV pressure which often causes MR jet velocities 
to be above 6 m/s.11 Because colour Doppler jet 
area is determined by jet momentum flux, a 6 m/s 
jet appears 44% larger than a 5 m/s jet through 
the same regurgitant orifice area. A large colour 
Doppler jet with a high driving velocity but small 
effective regurgitation orifice area is probably not 
severe MR, and is likely to appear less severe after 
SAVR/TAVR. Conversely, moderate or severe MR 
may lead to underestimation of the severity of AS, 
since decreased forward stroke volume due to MR 
lowers the flow across the aortic valve and, hence, 
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the aortic velocity and gradient (paradoxical low-flow low-gra-
dient aortic stenosis with preserved ejection fraction). In patients 
with combined AS and MR, these factors highlight the critical 
need for careful quantitative assessment of both lesions, using 
multiple quantitative and qualitative parameters.
does Mr impact the outcomes of patients with severe aortic 
valve stenosis?
Role of MR on SAVR outcomes
Whereas isolated AVR in elderly patients carries an acceptable 
mortality rate (estimated approximatively 1%–3%), the oper-
ative risk is significantly increased when double valve surgery 
is performed, with or without revascularisation. Indeed, in the 
Euro Heart Survey on Valvular Heart Disease, perioperative 
mortality for double valve intervention was 6.5% compared 
with 2.7% for isolated SAVR and 4.3% for SAVR combined 
with revascularisation.12 The latest report from the Society of 
Thoracic Surgeons reported a 3.5% mortality for double valve 
intervention over the last decade; however, when specifically 
looking at AVR combined with mitral valve surgery, periop-
erative mortality ranged from 8.2% to 11%.13 The decision 
to perform a single versus a double valve intervention should 
therefore be based on the severity of the disease, on the clinical 
status of the patient, the surgical risk evaluation and on the like-
lihood that MR will improve after SAVR. Table 1 lists the avail-
able studies observing the natural history of MR left untreated 
at the time of SAVR. Overall, these data suggest that MR is not 
a predictor of either early or late mortality, particularly when 
multivariate analysis was performed.1 14–22 However, Ruel et al 
found MR to be associated to a higher rate of heart failure (HF) 
symptoms, HF death and mitral valve repair/replacement need 
at follow-up, while Cutinho et al reported a 4.9-fold increased 
risk of mortality for patients in whom MR failed to improve 
after isolated SAVR.14 15 Barreiro et al examined a series of 
408 patients (62.8% primary MR), excluding severe MR, and 
found that moderate MR was a significant predictor of cumu-
lative late mortality.21 In the Placement of Aortic Transcatheter 
Valve (PARTNER) trial, moderate-to-severe MR was linked to 
higher 2-year mortality, with only a trend towards higher 30-day 
mortality.22 A meta-analysis by Harling et al reported poorer 
early and late outcomes associated with moderate-to-severe 
MR left untreated at the time of SAVR.23 However, this analysis 
included only four studies and a limited number of patients. The 
conclusions should be therefore considered provisional. This 
disparity between studies is likely due to different design and 
inclusion criteria; indeed, some studies included both primary 
and secondary MR and in some cases the MR group included 
trivial or mild MR. The studies are also confounded by lack of 
detail regarding mechanism of MR, or complete absence of such. 
Several studies reported 100% secondary MR in AS, which is 
highly doubtful because, as noted above, the mitral apparatus 
is usually calcified to some degree in patients with severe AS. 
Figure 1 Examples of different mitral regurgitation (MR) etiologies in patients with severe aortic stenosis. (A) Mitral valve with flail middle scallop 
of posterior leaflet (P2) and severe eccentric MR. (B) Mitral annulus calcification with bileaflet thickening and severe central MR. (C) Severe prolapse 
of middle scallop of posterior leaflet (P2) and severe MR by vena contracta area. (D) Normal mitral valve structure with restricted motion of the 
posterior leaflet due to inferior wall motion abnormality and associated severe MR.
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The majority of studies used only qualitative, subjective grading 
of MR severity or failed to report the methodology of MR 
grading. Only the PARTNER trial used core-laboratory adjudi-
cation of MR severity, but noted that the core laboratory did 
not perform any quantitative measures of MR severity.22 Most 
studies lumped moderate and severe MR together, presumably 
because severe MR is not commonly present in patients with 
severe AS. These limitations strongly limit the conclusions that 
can be drawn from the current literature.
Role of MR on TAVR outcomes
Significant MR (moderate or severe) appears to be present in 
15%–20% of patients undergoing TAVR and in this setting, it 
is often left untreated.24 How MR impacts on TAVR outcomes 
and how it changes after TAVR has been a focus of observa-
tional studies from single-centre and multicentre TAVR studies, 
with often conflicting results. Pooled results coming from two 
different meta-analyses have shown a higher mortality rate at 
30 days, 1 year and 2 years following TAVR in patients with signif-
icant MR.25 26 However, some of the primary studies (table 2), 
suggested an increase in early mortality after TAVR, whereas 
others did not.27–36 Moreover, MR was not been found to be a 
predictor of mortality in registries used to build the risk scores 
that are used or have been used for SAVR and/or TAVR.37 38 This 
might be due to the same limitations noted above. Most studies 
do not report the mechanism or aetiology of MR in patients 
who have undergone TAVR, nor is guideline-recommended 
integration of multiple quantitative and qualitative parameters 
used to grade MR. Moreover, different studies used different 
transcatheter heart valves (balloon-expandable vs self-expand-
able), frequently reporting different results. Whether the type 
of transcatheter heart valve has an influence on the impact of 
significant MR in TAVR patients will require confirmation in 
well-designed prospective studies.
does surgical or transcatheter AVr (sAVr or tAVr) reduce Mr 
severity?
The resolution of AS leads to an immediate drop in LV systolic 
pressure, which reduces the pressure gradient across the mitral 
valve, and therefore should improve MR severity. However, 
patient-prosthesis mismatch after SAVR or TAVR may limit the 
anticipated reduction LV pressure and thereby attenuate MR 
reduction. In the presence of secondary MR with mitral teth-
ering, the resolution of the AS can reduce mitral tenting area in 
the acute phase, which in turn leads to a decrease in MR severity. 
In the late postoperative period, reversed LV remodelling and/
or regression of LV concentric hypertrophy, could potentially 
reduce MR weeks after the intervention. In the PARTNER trial, 
MR improved in the majority of patients after SAVR and TAVR 
(69.4% vs 57.7%, respectively). However, it also worsened after 
SAVR or TAVR (2.8% and 5.8%, respectively). Although haemo-
dynamic success of SAVR or TAVR would be expected to improve 
MR severity, other factors could potentially worsen MR severity 
table 1 Association of MR severity with early and late mortality after SAVR
Author (ref) Year n Mr aetiology Mr grading
Early 
mortality time p Value
Late 
mortality
time 
(years)  Value
Multivariate 
analysis
Hr (95% cI)*
Absil18 2003 116 Secondary MR 100% None/mild
Moderate/severe
3.5%
7.0%
Perioperative 0.67 60.9%
55.0%
3.2±2.4 0.10 NR
Moazami1 2004 107 Secondary MR 100% Trivial/mild (72)
Moderate/severe 
(35)
NR
NR
– NR 10.9%
28.6%
5 0.04 NR
barreiro21 2005 408 Myxomatous 34.3%
Calcific 28.5%
Ischaemic 15.7%
Non-ischaemic 
21.4%
None/mild (338)
Moderate (70)
3.8%
7.1%
In-hospital 0.21 40.8%
41.4%
10 1.0 1.43 
(1.32 to 1.976)
ruel14 2006 848 Secondary MR 100% None/mild (741)
Moderate/severe 
(107)
NR – NR N/A 10 NR 1.8 (0.9 to 3.4)
caballero-
borrego20
2008 572 Secondary MR 100% No MR (419)
Non-severe MR 
(153)
5.6%
10.5%
NR 0.02 N/A – NR NR
Wan17 2009 182 Secondary MR 100% None/mild (91)
Moderate/severe 
(91)
NR 30 days NR 56.6%
51.7%
3.8±3.6 0.33 NR
takeda16 2010 193 NR None/mild (134)
Moderate/severe 
(59)
1.7%
2.9%
Operative 0.6 8.2%
8.5%
3.3±0.5 0.49 NR
barbanti22 2012 299 NR None/mild (240)
Moderate/severe 
(59)
7.1%
13.6%
30 days 0.09 71.9%
50.2%
1 0.04 1.77 
(1.17 to 2.68)
cotinho15 2013 255 Secondary MR 100% Severe MR untreated
Severe MR surgically 
treated
0.0%
1.1%
30 days 0.19 44.4%
23.3%
4.48±2.93 0.44 NR
schubert19 2016 423 Secondary MR 96%
Rheumatic 3%
Leaflet prolapse 1%
Mild (319)
Moderate/severe 
(105)
NR – NR 28.3%
38.2%
5 0.212 NR
MR, mitral regurgitation; NR, not reported; SAVR, surgical aortic valve replacement.
*Significant MR and late mortality.
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(table 3). Among these are atrial fibrillation, LV dyssynchrony to 
to new left bundle branch block or right ventricular pacing or 
ischaemic wall motion abnormalities.39 It has been reported that 
self-expandable valves have a higher incidence of residual AR 
mainly due to paravalvular leaks, particularly with deep implants 
that may result in the valve cage impinging on the anterior mitral 
leaflet.40 Severe MR due to a flail mitral leaflet would not be 
expected to improve after SAVR or TAVR, and likely requires 
either double valve replacement, or TAVR following by mini-
mally invasive or transcatheter mitral valve repair. The presence 
of patient-prosthesis mismatch, which is overall more common 
with SAVR than TAVR, might limit improvement in MR severity 
due to persistently high LV pressure. No studies have directly 
compared SAVR and TAVR in terms of MR reduction related to 
the presence of patient-prosthesis mismatch.
Is it necessary to intervene on mitral valve at the time of 
aortic valve intervention or should Mr be left alone?
Based on the existing literature, which is fraught with limita-
tions, there is still no clear pathway to follow when dealing with 
patients with concomitant AS and MR. However, a common 
sense approach based on symptoms, classification of AS severity, 
mechanism and severity of MR is proposed (figure 2). In 
table 3 Factors related to a decrease/increase in MR severity after aortic valve interventions (either surgical and percutaneous)
Factors related to decrease in Mr severity Factors related to increase in Mr severity
Reduced LV systolic pressure (haemodynamic success of SAVR/TAVR)
Reversal of LV remodelling
Patient-prosthesis mismatch (persistently high LV pressure)
Continued LV remodelling
Absence of mitral annular calcification Dilated mitral annulus
Secondary mitral regurgitation Primary mitral regurgitation
LVEDD≥50 mm Dilated left atrium
LVESD≥36 mm Dilated mitral annulus
Absence of atrial fibrillation Self-expanding valve with deep implant
Absence of pulmonary hypertension Moderate or greater aortic regurgitation
Mean gradient ≥40 mm Hg
Valve type (balloon-expandable)
Previous coronary artery disease or myocardial infarction
LVEDD, left ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameter; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
Figure 2 Proposed algorithm for the evaluation and management of patients with severe aortic stenosis (AS) and concomitant mitral regurgitation 
(MR). ASE, American Society of Echocardiography; CMR, Cine Magnetic Resonance; CRT, Cardiac resynchronization therapy; LV, left ventricular; 
MVR, mitral valve replacement; RHLC, Right and left heart catheterisation; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve 
replacement; TEE, Transesophageal Echocardiography.
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symptomatic patients with severe AS, a careful evaluation of the 
mechanism and severity of MR should be performed according 
to current guideline recommendations. If mild or moderate 
MR (stage B) is present, SAVR or TAVR can be performed per 
clinical indications and MR should not be treated as there is no 
indication for intervention for stage B MR. If MR is severe and 
secondary to LV dysfunction, guideline-directed medical therapy 
for HF/LV dysfunction should be optimally titrated, along with 
cardiac resynchronisation and/or revascularisation, if indicated. 
MR severity should then be re-evaluated. If severe MR persists 
despite optimisation of therapy, or there is a major anatomic 
defect, such as a flail leaflet, that would preclude improve-
ment of MR by valve replacement alone. Such patients could 
be considered for either a surgical double valve replacement, or 
a staged approach with SAVR or TAVR, followed by minimally 
invasive or transcatheter mitral valve intervention, depending on 
risk stratification, patient preference and other clinical factors. 
If no major anatomic defect is present, SAVR or TAVR should 
be performed and MR severity re-evaluated afterwards. If MR 
improves to mild or moderate, it can generally be left alone or 
managed medically. Persistence of severe MR requires careful 
reassessment. If the patient is asymptomatic, intervention may 
not be required. Resolution of AS may allow uptitration of guide-
line-directed medical therapy in patients with secondary MR 
after successful SAVR or TAVR. Symptomatic severe MR that 
persists or develops after SAVR or TAVR can be treated a mini-
mally invasive surgical valve repair or replacement, depending 
on the valve pathology. It is also possible to use transcatheter 
approaches, particularly in patients at high risk for surgery. 
There have been several reports of transcatheter edge-to-edge 
repair of MR after TAVR, but all are observational studies with 
significant methodological limitations. Reported mortality rates 
up to 1 year have been high, but this may be due to patient selec-
tion. Randomised controlled trials are needed to assess the real 
benefit of an additional mitral valve procedure over optimised 
medical therapy in patients with residual severe MR after SAVR 
or TAVR.
concLusIons
Severe AS and MR often coexist. Despite several observa-
tional studies and a post hoc analysis of PARTNER trial data, 
it has not been convincingly shown that MR is an independent 
predictor of adverse outcomes in AS. Although MR severity can 
either improve or worsen after SAVR or TAVR, it is difficult to 
accurately predict what might happen in an individual patient. 
Given the lack of high-quality data on mixed and multiple valve 
diseases and the virtual absence of randomised clinical trials on 
this topic, evidence-based recommendations for double valve 
intervention cannot be made. For now, careful patient evalua-
tion and clinical judgement must be used to identify those who 
might benefit from a double valve intervention versus a staged 
procedure in which mitral valve intervention is deferred until 
re-evaluation of MR severity after SAVR or TAVR.
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